Abbreviated Name

Lung Ref Set A App: Hirschowitz (2009)

Lead Investigator

Hirschowitz, Edward — University of Kentucky

Coordinating Investigator

Zheng, Yingye — Fred Hutchinson Cancer Center

Involved Investigators

• Srivastava, Sudhir — National Cancer Institute
• Ujhazy, Peter — National Cancer Institute
• Hirschowitz, Edward — University of Kentucky
• Zheng, Yingye — Fred Hutchinson Cancer Center

Abstract

No abstract availalbe.

Aims

Aim 1. To pre-validate assay performance in a high-risk clinical population from an alternate demographic. We intend to validate the predictive accuracy of our markers for clinically diagnosed lung cancer, identify the limits of the assay in individuals with benign lung disease, and determine marker specificity for lung vs. other cancers. Pre-validation will define performance in samples from an alternate demographic and generate classifiers with which to construct optimalperformance criteria that can be applied to class prediction for subsequent blinded analysis of a larger EDRN clinical reference set.

Analytic Method

Assay. The diagnostic chip includes capture proteins for the most predictive markers and empty T7 phage controls in replicates of eight, randomly distributed across the chip. The methodology for all studies will be identical to that described in published manuscripts and preliminary results section.

Outcome

We are continuing validation with two advanced objectives: 1) To evaluate assay performance for established lung cancer diagnosed in a clinical population 2) to confirm results that indicate this marker set may detect cancer and predict the onset of NSCLC prior to radiographic detection in a screened population.

Publications

• No publications available at this time for this protocol.

Biomarkers

• T7 (25 markers)

Data Collections

• No data collections available at this time for this protocol.

Start Date

Mar 26 2009

Estimated Finish Date

Mar 25 2010

Finish Date

Feb 27 2012

Protocol ID

279

Protocol Type

Reference Set

Fields of Research

• Proteomics

Collaborative Group

Lung and Upper Aerodigestive Cancers Research Group

Cancer Types

• Malignant neoplasm of bronchus and lung

Phased Status

1